Is ACKAY Stock Undervalued?
A comprehensive valuation analysis of Arcelik AS ADR (ACKAY) examining current multiples, intrinsic value, and comparing to analyst expectations.
Valuation Verdict
Fairly Valued
0.0% downside risk
Based on our analysis, Arcelik AS ADR appears to be fairly valued at the current price of $13.50.
Current Valuation Metrics
Valuation ratios help us understand how the market is pricing ACKAY relative to its fundamentals. Let's examine the key multiples investors are paying today.
Understanding the Metrics
- P/E Ratio: Not currently profitable or data unavailable.
- P/B Ratio: A P/B of 1.03 means investors pay $1.03 for every $1 of book value.
- P/S Ratio: The price-to-sales ratio of 0.14 indicates how much investors value each dollar of revenue.
- EV/EBITDA: This ratio of 4.05 helps compare ACKAY to peers while accounting for debt.
Fair Value Estimate
Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Arcelik AS ADR stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.
Unable to calculate a reliable fair value estimate due to insufficient financial data or negative cash flows. This is common for early-stage growth companies or those undergoing restructuring.
Investment Conclusion
Bottom Line
Arcelik AS ADR (ACKAY) appears fairly valued at $13.50, trading in line with our fundamental analysis. The stock may be appropriate for investors seeking exposure to Consumer Cyclical without significant valuation risk.
Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.
More Analysis for ACKAY
Compare with Peers
See how Arcelik AS ADR stacks up against similar companies
Popular Valuation Analysis
Explore valuation analysis for top stocks
Related: ACKAY Dividend, ACKAY Growth, ACKAY Financial Health
Compare: ACKAY vs AAPL, ACKAY vs MSFT, ACKAY vs GOOGL